Kleanthis G. Xanthopoulos, President & CEO at Regulus Therapeutics Inc. ("RGLS"), sold 3,505 shares at $7.00 ($25K) on 2014-05-27, disclosed to the SEC on 2014-05-29.
Scheduled sale ($25k) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.00 | 1,743 | $12K | 49.7% |
| 2 | $7.00 | 875 | $6K | 25.0% |
| 3 | $7.00 | 887 | $6K | 25.3% |
| Total | $7.00 avg | 3,505 | $25K | 100% |
| Filing → |
| RGLS | SELL | 2015-03-05 | $1.8M | — | Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |